Arcutis Biotherapeutics (ARQT) Current Assets (2019 - 2026)

Arcutis Biotherapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $438.1 million for Q1 2026.

• In Q1 2026, Current Assets rose 35.34% year-over-year to $438.1 million; the TTM figure through Mar 2026 stood at $438.1 million (up 35.34% YoY), while the FY2025 annual figure was $411.2 million, up 22.46% from the prior year.
• Current Assets for Q1 2026 stood at $438.1 million, up from $411.2 million in the prior quarter.
• The five-year high for Current Assets was $496.7 million in Q3 2022, with the low at $281.5 million in Q3 2023.
• The 5-year median for Current Assets is $358.9 million (2022), against an average of $376.1 million.
• The sharpest annual moves came in 2023 and 2024: Current Assets slumped 43.32% in 2023, then jumped 50.5% in 2024.
• Arcutis Biotherapeutics' Current Assets stood at $437.4 million in 2022, then fell by 24.46% to $330.4 million in 2023, then gained by 1.63% to $335.8 million in 2024, then advanced by 22.46% to $411.2 million in 2025, then grew by 6.52% to $438.1 million in 2026.
• Business Quant data shows ARQT's Current Assets at $438.1 million in Q1 2026, $411.2 million in Q4 2025, and $349.2 million in Q3 2025.